Combined Immune Deficiency (CID) Market Derives Impetus from Gene Therapy Offerings: Fact.MR

Improvements in rates of regulatory approvals and investments in gene editing and sequencing will aid the development of new, sustainable revenue streams for combined immune deficiencies.

Market research company Fact.MR’s recent report on the combined immune deficiency (CID)s market has projected strong growth rates through 2021 and years ahead. Higher risk of morbidity and fatalities from the covid-19 pandemic for patients with combined immune deficiency issues has boosted demand for the duration of the crisis period. Demand is likely to remain strong in the coming decade owing to increased prevalence of CID ailments and spending on the healthcare sector.

Genetic mutations are one of the leading causes for myriad immunity defects in terms of cell mediated and humoral parameters. CID patients are usually at lower risk of fatalities in comparison to patients with severe combined immunodeficiency issues, depending on specific mutations and gene defects.

Also known as primary immunodeficiency, CID ailments exist in more than 300 types. With CID issues potentially impacting respiratory systems, gastrointestinal tracts, nervous systems, urinary tracts, or sensory organs, the demand for treatments for combined immune deficiency will be sustained for the foreseeable future.

Wide ranging treatment options for CID conditions include stem cell transplants, bone marrow transplants, antibiotic therapy, immunoglobulin replacement therapy, and healthcare strategies to manage combined immunodeficiency diseases. Extensive investments into treatment research supports long-term prospects in the industry.

“In conventional cases, combined immune deficiency is largely characterized by immunologic phenotypes. Investments into research and development activities in the market are increasingly focused on the exploration of human gene facets that could result in these diseases. Genetic defect research will emerge as a major influencer for future developments,” comments a Fact.MR analyst.

Request a report sample to gain detailed insights at

Key Takeaways from Fact.MR’s Combined Immune Deficiency (CID) Market

  • Gene therapy treatments gain major market share owing to research investments and positive outcomes from clinical trials.
  • Antibody deficiency treatments hold the lead, owing to a wider range of treatment options.
  • United States holds major market share owing to widespread prevalence of immunity ailments.
  • Government investments towards healthcare research drives India as a lucrative market.

Combined Immune Deficiency (CID) Market – Prominent Drivers

  • Tech advances in gene therapy is a key driver in therapeutic research for CID treatment applications.
  • Rising cases of immunity ailments, among children and infants is driving research into combined immune deficiency issues.

Combined Immune Deficiency (CID) – Key Restraints

  • Lack of awareness about CID ailments among patients in developing countries is limiting market growth.
  • Lack of adequate diagnostic facilities are key factors holding back adoption of CID treatment options.

Discover more about the combined immune deficiency (CID) market with figures data tables and table of contents. You can also find detailed market segmentation at

Competitive Landscape

Leading players in the combined immune deficiency (CID) market include but are not limited to Baxter International Inc., LFB S.A., Biotest AG, Shire Plc, Grifols S.A., Kedrion Biopharma Inc., Sanquin , CSL Behring, China Biologic Products Holdings Inc., and Octapharma.

Major players in the combined immune deficiency (CID) market are investing intensively into product research and development efforts, in addition to industry collaborations to share expertise and boost product portfolios for ailment-customized treatments.

In March 2021, the innovative Genome Institute in collaboration with University of California, Berkeley, and UC San Francisco received FDA approval for a CRISPR test to correct genetic defects associated with sickle cell disease.

In April 2021, Bioverge Inc. announced the launch of an equity crowdfunding platform – Bioverge Portal for investments into treatments from private healthcare startups, via professional healthcare investors.

In November 2020, Mustang Bio Inc. joined hands with Minaris Regenerative medicine in an agreement for technology transfer and GMP production for research on MB-107 lentiviral gene therapy for X-linked severe combined immunodeficiency.

More Insights on the Combined immune deficiency (CID)s Market

In its latest report, Fact.MR offers unbiased analysis of the global combined immune deficiency (CID)s market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of disease type (antibody deficiency, cellular immunodeficiency, innate immune disorders), therapy type (immunoglobulin replacement therapy, bone marrow transplant, stem cell transplant, lung transplant, gene therapy, and others), and end user (hospitals, ambulatory surgical care, and research & development institutes) across seven regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa).

Explore Fact.MR’s Coverage on the Healthcare Domain

Factor XIII Deficiency Treatment Market: A recent study by Fact.MR on the factor XIII treatment market offers a 10-year forecast for 2018 to 2028. The study analyzes key trends that are currently determining the growth of the market. This report covers vital dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players.

Immune Response Testing Market: Fact.MR’s extensive coverage on the immune response testing market offers in-depth insights about the prominent growth dynamics that are likely to aid expansion of prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the landscape.

Radioimmunotherapy (RIT) Market: The global radioimmunotherapy (RIT) market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in forthcoming years.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Follow Us: LinkedIn | Twitter
Market Intelligence Services:
Source: Fact.MR

Back to news